Objectives: In our study we investigated the possible effects of levetiracetam (LEV) on hepatic fibrosis in streptozotocin (STZ) induced diabetic rats with histopathology, real-time elastography imaging technique. We also aimed to investigate the effects of LEV on oxidative stress markers. Materials and methods: Diabetes was induced by intraperitoneal (i.p.) single dose injection of STZ (60 mg/kg). Twenty-one rats were randomly divided into three groups; control group, STZ group treated with 1 mL/kg/day saline (STZ+SP), and STZ group treated with 600 mg/kg/day LEV was administrated by i.p. for four weeks. All rats underwent a real-time elastography (strain-elasticity %). The liver sections are examined by histopathologically (liver fibrosis score). In addition, malondialdehyde, total antioxidant capacity, and glutathione levels were measured in plasma. Results: Treatment with LEV significantly decreased liver fibrosis score and increased strain measurement % on the real-time elastography in diabetic rats. In addition, treatment with LEV significantly increased total antioxidant capacity, glutathione and malondialdehyde levels decreased in plasma of diabetic rats. Conclusion: Levetiracetam has potential as a treatment for diabetic liver injury and hepatic fibrosis and can be a good candidate among new treatment options. In addition, real-time elastography is reliable imaging non-invasive technique for detecting hepatic fibrosis.
Type 2 diabetes mellitus and hyperinsulinemia are closely associated with the development of fatty changes in the liver ranging from simple steatosis to steatohepatitis to advance liver disease such as hepatic fibrosis and cirrhosis. [1, 2] Despite extensive studies, the underlying mechanisms of these liver diseases still remain largely undefined. Evidence of oxidative stress with decreased antioxidant defenses has been found to be associated with hepatic fibrosis regardless of etiology and fibrosis progression rate. [3, 4] Although there are few effective therapies used for the treatment of hepatic fibrosis, no drug has been approved as anti-fibrotic agent in humans so far. [5, 6] The benefit of the agents reducing the oxidative stress, inflammation and immune response were determined in the previous studies and to date, only limited antifibrogenic treatment options are available to protect hepatocytes from oxidative stress and reduce inflammatory damage. In the previous studies they have shown that different types of antioxidants could attenuate the complications of diabetes including fatty liver diseases and fibrosis. [7] [8] [9] Levetiracetam (LEV) is a commonly used antiepileptic drug that acts as a histone deacetylase inhibitor and an inhibitor of highvoltage activated N-type calcium channels. The recent evidence shows that the drug has antiinflammatory and antioxidative effects. [10] [11] [12] In a previous experimental study the neuroprotective effects of LEV by reducing the level of oxidative stress markers and anti-inflammatory cytokines were determined. [10] On account of this results LEV may be a promising candidate for treating other inflammatory diseases such as hepatic fibrosis.
In this present study we aimed to investigate the possible effects of LEV on hepatic fibrosis in streptozotocin (STZ) induced diabetic rats with histopathology and real-time elastography imaging technique. We also aimed to investigate the effects of LEV on oxidative stress.
MATERIALS AND METHODS

Animals
In this study 21 male Sprague Dawley albino mature rats at eight weeks, weighing 200-220 g, were used. Animals were fed ad libitum and housed impairs in steel cages having a temperaturecontrolled environment (22±2 °C) with 12-h light/ dark cycles. The experimental procedures were approved by the Committee for Animal Research of Ege University. All animal studies are strictly conformed to the Animal Experiment Guidelines of the Committee for Human Care.
Experimental protocol
Diabetes was induced by intraperitoneal (i.p) injection of STZ (Sigma-Aldrich, Inc.; Saint Louis, MO, USA) (60 mg/kg in 0.9% NaCl, adjusted to a pH 4.0 with 0.2M sodium citrate) for 14 rats. No drug was administered to the remainder of rats (n=7) (Control group). Diabetes was verified after 24 hours by evaluating blood glucose levels with the use of glucose oxidase reagent strips (Boehringer-Mannheim Corp, Indianapolis, IN). The rats with blood glucose levels 250 mg/dL and higher were included in this study. We waited 21 days for the development of diabetes-related microvascular complications. [13] Then, 14 diabetic rats were randomly divided into two groups; STZ group treated with 1 mL/kg saline (STZ+SP) (n=7), and STZ group treated with 600 mg/kg/day LEV (Keppra falcon, UCB, Greece) (STZ+LEV) (n=7) was administrated by i.p for four weeks.
Histopathological examination of liver
For histological studies, all animals were anesthetized by an i.p. of ketamin (40 mg/kg)/ xylazine (4 mg/kg) and perfused with 200 mL of 4% formaldehyde in 0.1 M phosphate-buffer saline (PBS). Formalin-fixed liver sections (4 μm) were stained with Masson's trichrome. All sections were photographed with Olympus C-5050 digital camera mounted on Olympus BX51 microscope (Olympus optical Co. Ltd., Hatagaya, Shibuya-ku, Tokyo, Japan).
Morphological analysis was assessed by computerized image analysis system (Image-Pro Express 1.4.5, Media Cybernetics, Inc. USA) on 10 microscopic fields per section examined at a magnification of x40, with the observer blind to the study group. Histological lesions (fibrosis) were evaluated according to the following scale: 0= absent; 1= mild (involving 10% per microscopic field); 2= moderate (>11 and 25%); 3= severe (>26 and 50%) or 4= very severe (>50%).
Real-time elastography
Elastography measures mechanically induced deformation (strain) of structures in the B mode image to quantify the elasticity of the tissue. By measuring the tissue strain induced by compression, it is possible to estimate the tissue hardness.
Transabdominal real-time elastography was proposed as a new method for noninvasive staging of liver fibrosis relative tissue elasticity is calculated and displayed as a color overlay of the conventional B-mode image.
Stiffer tissue (low elasticity) structures are displayed in blue, while the more easily deformed tissues (high elasticity) are in red. If there is an increase in liver fibrosis is reduced strain (elasticity), so the color turns blue and strain measured the percent (%) value is reduced. [14, 15] 
Strain (elasticity) measurement
All groups underwent real-time elastography (EUB-8500, Hitachi Hi-Vision Avius; 9-MHz probe, Japan). The rats were examined in a supine position. An area was chosen where the liver tissue was at least 3 cm thick and was free of large blood vessels. Strain measurements of circular ROI (Region of Interest) were used. ROI was placed 0.5 cm lateral to the portal vein.
The examination was performed with a 9-MHz transducer because, similar to B-mode imaging, higher frequencies allow better analysis of areas close to the transducer, and assessment of realtime elastography is optimized by the manufacturer on superficial tissues. The measurement depth was between 10 and 15 mm (mean, 12 mm) with a 80-90 mm 2 area of measurement (mean, 85 mm 2 ). 5-10 minutes per rats ( Figure 1 ).
Measurement of lipid peroxidation
Lipid peroxidation was determined in plasma samples by measuring malondialdehyde (MDA) levels as thiobarbituric acid reactive substances. [16] Briefly, trichloroacetic acid and thiobarbituric acid reactive substances (TBARS) reagent were added to the plasma samples, then mixed and incubated at 100 °C for 60 min. After cooling on ice, the samples were centrifuged at 3000 rpm for 20 min and the absorbance of the supernatant was read at 535 nm. Malondialdehyde levels were calculated from the standard calibration curve using tetraethoxypropane and expressed as μM.
Measurement of plasma total antioxidant capacity (TAC)
Plasma total antioxidant capacity was measured by ferric reducing antioxidant power (FRAP) assay according to Benzie and Strain. [17] Briefly, the FRAP reagent (sodium-acetate, tripiridiltriazyne in hydrochloric acid and ferric chloride) prewarmed to 37 °C were mixed with plasma; the absorbance was read after 4 min at 593 nm. A calibration curve was prepared by substituting the sample with freshly prepared of ascorbic acid solution (100-1000 μM).
Measurement of plasma glutathione (GSH) levels
Glutathione content in plasma samples was measured spectrophotometrically according to Ellman's method. [18] In this method, thiols interact with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) and form a colored anion with maximum peak at 412 nm. Glutathione levels were calculated from the standard calibration curve and expressed as μM.
Statistical analysis
All quantitative data were analyzed by using non-parametric (Mann-Whitney U) test. Student's t test was used to evaluate the differences between the groups. Data are presented as mean values ± standard error of the mean (SEM). P values of 0.05 or less were regarded as statistically significant. Figure 1 shows tissue elasticity distribution displayed as a color overlay of the conventional B-mode image. Stiffer or fibrotic tissue (low elasticity) structures are displayed in blue, while the more easily deformed or low fibrotic tissues (high elasticity) are in red. If there is an increase in liver fibrosis is reduced strain (elasticity), so the color turns blue and strain measured the percent (%) value is reduced. Figure 2 shows histopathological sections of control rat liver and LEV-treated diabetic rat liver induced by STZ. The liver histopathology of the STZ+SP group showed significantly higher liver fibrosis score when compared with the control group (p<0.001). We also observed notably reduced liver fibrosis score in the STZ+LEV group when compared with the STZ+SP group (p<0.05). The STZ+SP group showed significantly decreased strain on the real-time elastography when compared with control the group (p<0.001). We also observed notably increased strain in the STZ+LEV group when compared with the STZ+SP group (p<0.001). Table 1 shows the results of liver fibrosis score and strain measurement of control rat liver and diabetic rat liver induced STZ. Table 2 shows the results of GSH, TAC, and MDA levels in the plasma of diabetic rats induced STZ. The STZ+SP group showed significantly decreased total TAC, GSH and increased MDA levels when compared with the control group. The STZ+LEV group showed significantly increased total TAC, GSH and decreased MDA levels when compared with the STZ+SP group.
RESULTS
DISCUSSION
In this present study we have shown the protective antioxidant effects of LEV on hepatic fibrosis in STZ induced diabetic rats with histological examination, real-time elastography imaging technique and measurement of oxidative and antioxidative markers. Our result was consistent with the other studies and showed that type 2 DM and hyperglycemia are major risk factors for diabetic hepatic injury. [9] Pathogenesis of diabetic liver injury comprises two steps. The first step is thought to be insulin resistance increasing the transport of fatty acids from adipose tissue to the liver and causes accumulation of fat in the hepatocytes. In the second step increased oxidative stress and production of inflammatory cytokines lead to the hepatocellular injury and subsequently progress to hepatic fibrosis. [19, 20] Pro-inflammatory and profibrogenic role of oxidative stress products play a critical role in this step. [21] In the previous studies, increased levels of lipid peroxidation products and oxidative stress markers and decreased levels of antioxidant enzymes are found in nonalcoholic steatohepatitis (NASH) patients. [22, 23] In prior reports the protective effect of antioxidants and stimulation of collagen production and hepatic fibrogenesis by oxidative stress were shown. [3, 24] Oxidative stress-related molecules may act as mediators and trigger the events responsible for the progression of hepatic fibrosis. [4] Reactive oxygen species (ROS) trigger formation of cytokines and growth factors leading to inflammatory response and eventually liver damage.
Currently, liver biopsy is still the gold standard for determining hepatic fibrosis. In spite of this, it is an invasive and extremely uncomfortable procedure, and sometimes may result with serious complications. [25, 26] Besides, significant intraand interobserver variability is reported in the pathologic evaluation of the specimens. [27, 28] As a consequence, the evaluation of non-invasive methods for liver fibrosis assessment has become important in recent researches. Real-time elastography is a method used for the detection of focal lesions in the breast, thyroid gland, and prostate gland. [29] In a previous study, they had shown that real-time elastography can be used for the measurement of liver fibrosis in patients with chronic viral hepatitis. [14] In a recent study, Lin et al. [30] used real-time elastography as a reliable imaging technique for quantitative evaluation of hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats. They compared the results of real-time elastography [acquire area ratio of low-strain region (% AREA) and liver fibrosis index] with the stage of liver fibrosis and grade of necroinflammatory pathologically. They determined that the values of liver fibrosis index and low-strain region were both increased with liver fibrosis stage. They found a certain correlation between liver fibrosis index and liver fibrosis stage, so as low-strain region and liver fibrosis stage. In this present study, perivascular fibrotic alterations in the liver was determined in diabetic rats histopathologically and lower strain measurement was found by using real-time elastography.
Levetiracetam is an antiepileptic drug which has been proved to have antioxidative and antiinflammatory efficacy. [10] [11] [12] It was demonstrated that besides the antiepileptic efficiency of the drug LEV has neuroprotective effects associated with the reduction of lipid peroxidation, and the increase of the level of endogenous antioxidants. [11] Levetiracetam also regulates the influx of calcium into the cells, and modulates membrane depolarization and prevents irreversible cellular damage. [31] [32] [33] In this present study we determined the protective antioxidant effects of LEV on hepatic fibrosis. Significant increases were detected in the serum levels of GSH and TAC while there was a significant decrease in the serum levels of MDA in the LEV+STZ group. Much evidence supports the association between oxidant injury and hepatic fibrogenesis. [34] It was reported that a well known antioxidant molecule vitamin E, reduced the level of lipid peroxidation molecules in the liver of STZ-diabetic rats and prevented the development of diabetic hepatic injury. [8] Another well-known antioxidant molecule melatonin was used in a study and significant decrease in an oxidative stress parameter, MDA, in brain, liver and kidney was determined. [8] In another study by using angiotensin converting enzyme inhibitor to protect liver damage in STZ-induced diabetic rats, they had shown the negative correlation between liver tissue fibrosis and glutathione related antioxidant defenses. [9] As a result we showed that when compared with histological investigation, real-time elastography is a reliable imaging technique for detecting hepatic fibrosis. Taken together the mechanism of action of LEV and pathogenesis of diabetic liver injury, LEV has potential as a treatment for diabetic liver injury and hepatic fibrosis and can be a good candidate among new treatment options. Given the scope of the problem more evidence is needed for the effectiveness and safety of this drug and future prospective and randomized studies will be needed to confirm recommendations.
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